Enzychem Lifesciences Corporation (183490.KQ)
KRW 1329.0
(-2.71%)
KRW 1329.0
(-2.71%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.65 Billion KRW | -85.03% |
| 2022 | 37.77 Billion KRW | -27.32% |
| 2021 | 51.97 Billion KRW | 20.69% |
| 2020 | 43.06 Billion KRW | 1293.95% |
| 2019 | 3.08 Billion KRW | -20.18% |
| 2018 | 3.87 Billion KRW | -30.74% |
| 2017 | 5.58 Billion KRW | -0.21% |
| 2016 | 5.6 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 5.07 Billion KRW | -10.22% |
| 2024 Q2 | 4.29 Billion KRW | -15.38% |
| 2023 Q1 | 9.52 Billion KRW | -74.8% |
| 2023 FY | 5.65 Billion KRW | -85.03% |
| 2023 Q3 | 6.09 Billion KRW | -1.43% |
| 2023 Q2 | 6.18 Billion KRW | -35.07% |
| 2023 Q4 | 5.65 Billion KRW | -7.17% |
| 2022 Q2 | 56.68 Billion KRW | 4.82% |
| 2022 Q1 | 54.07 Billion KRW | 4.04% |
| 2022 Q4 | 37.77 Billion KRW | -35.36% |
| 2022 FY | 37.77 Billion KRW | -27.32% |
| 2022 Q3 | 58.44 Billion KRW | 3.11% |
| 2021 Q4 | 51.97 Billion KRW | 3.88% |
| 2021 Q2 | 48.16 Billion KRW | 5.61% |
| 2021 Q3 | 50.03 Billion KRW | 3.88% |
| 2021 Q1 | 45.61 Billion KRW | 6.39% |
| 2021 FY | 51.97 Billion KRW | 20.69% |
| 2020 Q4 | 42.87 Billion KRW | 236.93% |
| 2020 FY | 43.06 Billion KRW | 1293.95% |
| 2020 Q1 | 3.26 Billion KRW | 11.96% |
| 2020 Q3 | 12.72 Billion KRW | 39.12% |
| 2020 Q2 | 9.14 Billion KRW | 180.55% |
| 2019 Q4 | 2.91 Billion KRW | -17.29% |
| 2019 FY | 3.08 Billion KRW | -20.18% |
| 2019 Q1 | 3.75 Billion KRW | -2.92% |
| 2019 Q3 | 3.52 Billion KRW | 15.19% |
| 2019 Q2 | 3.05 Billion KRW | -18.66% |
| 2018 Q1 | - KRW | -100.0% |
| 2018 FY | 3.87 Billion KRW | -30.74% |
| 2018 Q2 | 5.34 Billion KRW | 0.0% |
| 2018 Q3 | 4.53 Billion KRW | -15.19% |
| 2018 Q4 | 3.87 Billion KRW | -14.61% |
| 2017 FY | 5.58 Billion KRW | -0.21% |
| 2017 Q4 | 5.58 Billion KRW | 0.0% |
| 2016 FY | 5.6 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 23.72 Billion KRW | 76.159% |
| CMG Pharmaceutical Co., Ltd. | 19.74 Billion KRW | 71.347% |
| Celltrion Pharm, Inc. | 162.52 Billion KRW | 96.519% |
| Huons Global Co., Ltd. | 254.93 Billion KRW | 97.781% |
| DongKook Pharmaceutical Co., Ltd. | 104.74 Billion KRW | 94.599% |
| Humedix Co., Ltd. | 2.7 Billion KRW | -109.383% |
| Boditech Med Inc. | 10.56 Billion KRW | 46.47% |
| EuBiologics Co., Ltd. | 14.77 Billion KRW | 61.722% |
| FutureChem Co.,Ltd | 3.68 Billion KRW | -53.617% |
| Huons Co., Ltd. | 124.61 Billion KRW | 95.46% |
| BNC Korea Co., Ltd. | 737.2 Million KRW | -667.356% |
| AptaBio Therapeutics Inc. | 13.93 Billion KRW | 59.402% |